Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Divi’s Laboratories Limited ( (IN:DIVISLAB) ) has shared an announcement.
Divi’s Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2025, reporting a total income of 2,476 crore and a profit of 557 crore. The results, approved by the Board of Directors, indicate a stable financial performance with no discontinued operations, reflecting the company’s ongoing commitment to its core pharmaceutical manufacturing operations.
More about Divi’s Laboratories Limited
Divi’s Laboratories Limited is a prominent company in the pharmaceutical industry, specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients. The company focuses on a single reportable business segment, maintaining a strong presence in the pharmaceutical manufacturing sector.
Average Trading Volume: 13,601
Technical Sentiment Signal: Buy
Current Market Cap: 1688.1B INR
For detailed information about DIVISLAB stock, go to TipRanks’ Stock Analysis page.